Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1

September 3, 2024 8:30 AM

Moderna, Inc. (Nasdaq:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorized its updated COVID-19 vaccine targeting the JN.1 variant of SARS-CoV-2.Following the MHRA decision, doses will be available for eligible groups as part of the NHS autumn vaccination program, which is prioritized for use in people at greatest risk of serious illness from COVID-19.For the first time in the UK, the updated...

Read more

Modern Foot & Ankle Acquires Florida Orthopedic Foot and Ankle Center in Sarasota, Florida

September 3, 2024 8:15 AM

Dr. James Cottom, renowned lower extremity surgeon, joins the Modern Foot & Ankle team, enhancing and expanding their expertise across nearly 25 offices in Florida and Texas.SARASOTA, FL / ACCESSWIRE / September 3, 2024 / Modern Foot & Ankle proudly announces the acquisition of Florida Orthopedic Foot and Ankle Center (FLOFAC) in Sarasota, Florida. This expansion brings Modern Foot & Ankle's presence to nearly 25 offices, serving patients across...

Read more

Lyme ImmunoBlot Receives FDA Clearance

September 3, 2024 8:00 AM

Newly Cleared Technology is a Game Changer for the Diagnosis of an Often Debilitating DiseaseMILPITAS, CA / ACCESSWIRE / September 3, 2024 / ID-FISH Technology, Inc., a leading provider of diagnostic tools for the detection of tick-borne diseases, today announced that its Lyme ImmunoBlot test has received FDA clearance. The name of the test is iDart™ Lyme IgG ImmunoBlot Kit. ID-FISH Technology Logo The iDart Lyme IgG ImmunoBlot Kit is a...

Read more

PaxMedica Secures Immediate Exercise of Warrants

September 3, 2024 8:00 AM

PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per...

Read more

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

September 3, 2024 7:30 AM

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024Format: Fireside ChatDay/Time: Tuesday, September 10 at 1:30 P.M....

Read more

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

September 3, 2024 7:00 AM

Theralase® Technologies Inc. is currently seeking partnerships / licensing opportunities in the commercial development of this latest discoveryTORONTO, ON / ACCESSWIRE / September 3, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations,...

Read more

AQ Pharmaceuticals, Inc. Announces Results of JBA Brands Study: Insights Into Collagen-GlucoTrojan and Its Potential Role in Metabolic Health and GLP-1

September 3, 2024 7:00 AM

GARDEN GROVE, CA / ACCESSWIRE / September 3, 2024 / AQ Pharmaceuticals, Inc. (AQP), in collaboration with Tastermonial Inc., is pleased to announce successful results from a real-world, open-label study evaluating JBA Collagen-GlucoTrojan®. Led by Dr. Guillermo Repizo and Bude Sethaputra-Piccin, CEO of Tastermonial, the study explores Collagen-GlucoTrojan® for its potential benefits in metabolic health. Given the growing interest in GLP-1...

Read more

Self-administered Biologics Market Expected to Grow at 4.5% CAGR through 2034 | Future Market Insights, Inc.

September 3, 2024 5:10 AM

As per Future Market Insights' latest industry analysis, the self-administered biologics market was valued at around USD 90,007.3 Million in 2023 and is anticipated to exhibit a CAGR of 4.5% over the forecast period (2024-2034).Self-administered insulin injections are an important part of the diabetes dosage regime. Self-administered insulin offers convenience and flexibility to patients in managing their diabetes.The market is characterized by...

Read more

iZafe Group Introduces a Groundbreaking Tripartite Collaboration Aimed at Enhancing Independence and Safety in Medical Care

September 3, 2024 4:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / September 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB ("iZafe Group") today announces a strategic tripartite collaboration with Zafe Care Systems AB and Sensorem AB. This partnership, building on previous successes in municipal care, represents a significant step forward in providing users with increased independence and safety in their medication management, regardless of their location.Dosell has...

Read more

Bioz and Resonac America (Shodex) Partner to Enable Researchers to Leverage Citations to Choose Analytical Liquid Chromatography Products

September 3, 2024 4:00 AM

PALO ALTO, CA / ACCESSWIRE / September 3, 2024 / Bioz, Inc., an innovative research-focused AI company, is pleased to announce its partnership with Resonac America, a globally recognized company in the field of liquid chromatography (LC). Its ShodexTM brand LC columns have been manufactured by Showa Denko K.K. (Resonac Corporation as of 2023) in Japan since 1973. Shodex is best known for innovative polymer-based columns offering size-exclusion...

Read more

Evotec Announces Change in Management Board

September 3, 2024 1:50 AM

Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) today announced that its Chief Business Officer, Dr Matthias Evers, has decided to step down to pursue opportunities outside of Evotec. He will leave the Company effective 01 October 2024. Matthias was appointed Chief Business Officer of Evotec on 01 May 2022.Prof. Dr Iris Löw-Friedrich, Chairwoman of the Supervisory Board of Evotec, said: "Over the past...

Read more

Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1

September 2, 2024 7:00 AM

CAMBRIDGE, MA / ACCESSWIRE / September 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Taiwan Food & Drug Administration (FDA) has approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1., for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.In April 2024, the World Health Organization (WHO) Technical Advisory Group on...

Read more

Enteric Softgel Capsules Market Is Expected to Reach USD 582.5 Million Grow at A CAGR of 6.7% by 2033 | FMI Inc.

September 2, 2024 6:15 AM

The global enteric softgel capsules market is poised for significant growth over the next decade, according to recent research by Future Market Insights. The market, valued at USD 288.8 million in 2022, is expected to reach USD 305.3 million in 2023, reflecting a year-over-year growth rate of 5.7%. Looking ahead, the market is projected to expand at a compound annual growth rate (CAGR) of 6.7%, reaching a valuation of USD 582.5 million by...

Read more

Hemogenyx Pharmaceuticals PLC Announces CDX Development Update

September 2, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO)("Hemogenyx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical group focused on developing treatments for cancers and viral diseases, is pleased to announce that it has developed a new and improved version of its bi-specific antibody ("CDX") for the treatment of relapsed/refractory acute myeloid leukaemia ("AML"), a subset of acute lymphoblastic leukaemia ("ALL"), and potentially for...

Read more

Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

September 2, 2024 1:20 AM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE® will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium being held in Porto, Portugal. The...

Read more

Black Book Highlights What’s Hot and What’s Not for 2025, VC and PE Healthcare IT Investments Survey Research

September 1, 2024 12:00 PM

Black Book's 2025 survey highlights trends and investment priorities in healthcare IT, based on insights from over 1,160 key figures in venture capital, private equity, and healthcare banking.NEW YORK, NY / ACCESSWIRE / September 1, 2024 / In Q3 2024, Black Book conducted a comprehensive survey of 1,160 key figures in healthcare banking, private equity, advisory firms, and venture capital with the goal to assess their investment outlook and...

Read more

Therapist to Coach Solutions Helps Therapists Build Coaching Businesses

August 30, 2024 4:45 PM

Therapist to Coach Solutions, an innovative platform designed to help therapists transition to or add a coaching business, officially launched August 1, 2024. Founded by seasoned tech entrepreneur Mike Rhonek, the platform offers a comprehensive suite of tools and resources to enable therapists to build successful coaching businesses.Photo: Unsplash.com Identifying the GapRhonek's inspiration for creating Therapist to Coach Solutions...

Read more

GLG Life Tech Corporation Provides Update Regarding Delisting From TSX And Listing on NEX

August 30, 2024 3:23 PM

GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a global and agricultural leader in the natural zero-calorie sweetener industry, committed to the sustainable development of high-quality zero-calorie natural sweeteners, is providing an update regarding the Company's delisting review initiated by the Toronto Stock Exchange ("TSX") and the Company's upcoming transfer of its listing to the NEX exchange.As previously announced, the TSX...

Read more

As Far as Anyone in Gaza Knew, No One Here Had Contracted Polio in a Quarter-Century. Until Abdelrahman

August 30, 2024 11:00 AM

NORTHAMPTON, MA / ACCESSWIRE / August 30, 2024 / CARE:The latest on polio in GazaSign up for the CARE News & Stories email newsletter to find out more about what's happening around the world through vibrant, engaging stories that put humanity at the center.SubscribeAbdelrahman was born in September 2023. The Gaza escalation displaced him and his family from the north of Gaza to Deir Al-Balah, then to Rafah, and then back to Deir Al-Balah again,...

Read more

AGAPE ATP Corporation Addresses Recent Corporate Exercise and Strategic Developments

August 30, 2024 9:00 AM

AGAPE ATP Corporation (NASDAQ:ATPC) ("ATPC" or "the Company"), is pleased to announce a series of significant updates reflecting its ongoing commitment to growth and sustainability.Effective today, ATPC will implement a 1-for-20 reverse stock split of its shares of common stock, as previously disclosed in filings with the Securities and Exchange Commission. This strategic action aims to increase the market price per share, thereby meeting...

Read more